



OESO Zoom Conference 2022

*Topics in benign and malignant
Diseases of the Esophagus*

28th October 2022

13:00 – 13:20 : Introduction – News from OESO

R. Giuli (France), H. Mashimo (USA)

13:20 – 13:30 : Introduction – Welcome from Geneva University Hospital

C. Toso (Switzerland), S.P. Mönig (Switzerland)

13:30-15:30 : Benign esophageal plenary session

Chair: H. Mashimo (USA), B. Müller (Germany), RP. Tatum (USA)

Panel: M. Chevallay (Switzerland), H.J. Chon, J.O. Clarke (USA), M. Hongo (Japan),

O. Huber (Switzerland), M. Jung (Switzerland), S.P. Mönig (Switzerland), B. Müller (Germany)

- Should manometry or the Functional Lumen Imaging Probe (FLIP) be the initial test for a patient with non-obstructive dysphagia?
A. Khan (USA)
- What is the safest surgical approach for treatment of epiphrenic diverticulum?
J. Moremen (USA)
- Should we avoid Nissen fundoplication altogether and perform partial posterior (Toupet) fundoplication for all patients?
M.B. Ujiki (USA)
- Should we still perform Nissen fundoplication preferentially over partial fundoplication except in cases of severely ineffective or absent esophageal motility?
R.B. Yates (USA)
- Which patients would likely benefit most from magnetic lower esophageal sphincter augmentation compared to other antireflux procedures?
E. Asti (Italy)
- Which patients would likely benefit most from combined laparoscopic hiatus hernia repair with transoral incisionless fundoplication (C-TIF) compared to other antireflux procedures?
P. Gatta (USA)
- How often do we see clinically significant GERD after per-oral endoscopic myotomy (POEM) and what are the best strategies for management when it occurs?
B. Louie (USA)
- What is the current role for mucosal integrity testing in clinical management of esophageal disease?
J. Lee (Malaysia)
- What is the best way to assess for potential laryngopharyngeal reflux?
W.W. Chan (USA)
- What do you tell your patients about proton pump inhibitor safety?
D. Jodorkovsky (USA)
- Which patients do you see benefiting most from potassium competitive acid blockers?
K. Lynch (USA)
- Are there patients with eosinophilic esophagitis who can be observed without treatment?
N. Fernandez-Becker (USA)
- What is the best management of esophageal perforations?
M. Read (Australia)

15:30 – 16:00 : Break

16:00 – 17:30 : Malignant topics session

Chair: S.P. Mönig (Switzerland), A. Davies (UK), Y-S. Mao (China), P.M. Schneider (Switzerland)

Panel: F. Berth (Germany), P.W.Y. Chiu (Hong Kong), D. Collet (France), A. Davies (UK),
T. Goetze (Germany), K.A. Goodman (USA), S. Gisbertz (Netherlands), I. Gockel (Germany),
B. Müller (Germany), H. Mashimo (USA), M. Read (Australia), T. Schmidt (Germany),
J. Zacherl (Austria)

- Is PET-CT necessary for diagnosis of metastatic esophageal cancer ?
P.M. Schneider (Switzerland)
- In which case of adenocarcinoma of the esophagus do we have to do chemotherapy or radiochemotherapy ?
T. Schmidt (Germany)
- Can we perform limited resection in ECG cancer ?
P. Grimminger (Germany)
- What are the advantages of robotic esophagectomy ?
PW.Y. Chiu (Hong Kong)
- What are the limits of the endoscopic resection ?
S. Seewald (Switzerland)
- What should be the extent of lymphadenectomy ?
S. Gisbertz (Netherlands)
- What is the role of immunotherapy in the global management of esophageal cancer ?
M. Möhler (Germany)
- Oligometastatic situation
M. Chevallay (Switzerland)
- Wait and see strategy : which place in our management – radio-oncological point of view ?
K.A. Goodman (USA)
- Wait and see strategy : which place in our management – surgical point of view ?
B. Wijnhoven (Netherlands)

17:30-18:00 : OESO Worldwide Pilot Centers